Investigational drug · Phase 2
RBD4059
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Stable Coronary Artery Disease CAD.
Phase 2Last checked: Nov 19, 2026Latest source record: May 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "RBD4059"
First trial start
2024
Aug 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RBD4059", any sponsor or status.
Conditions studied
As listed on its trial records.
- Stable Coronary Artery Disease CAD
Approved drugs for the same conditions: Coronary artery disease and heart attack
Largest trials
Live from ClinicalTrials.gov: studies naming "RBD4059" as an intervention, largest first.
Suzhou Ribo Life Science Co. Ltd.Industry
NCT05653037 · 32 participants · Start Mar 21, 2023 · Primary completion Oct 1, 2024
Drug: RBD4059; Placebo · For: Healthy Volunteers
Sites: Brisbane, Australia
- Phase I Trial of RBD4059 in Chinese Healthy ParticipantsNot yet recruiting
Suzhou Ribo Life Science Co. Ltd.Industry
NCT07930767 · 30 participants (planned) · Start Dec 2026 · Primary completion Aug 2027
Drug: RBD4059; Placebo · For: Healthy
Ribocure Pharmaceuticals ABIndustry
NCT06717074 · 30 participants · Start Aug 28, 2024 · Primary completion Apr 29, 2026
Drug: RBD4059; Placebo · For: Stable Coronary Artery Disease CAD
Sites: Mölndal, Sweden
Newest research
PubMed records naming it or its code names, newest first.
- RNA interference therapy targeting coagulation factor XI: a first-in-human trial of RBD4059 (vortosiran).
Gabrielsen A, Ueckert S, Nilsson C, et al. · Blood Adv 2026
- Inhibition of Factor XI Using RBD4059: A Novel GalNAc-siRNA With Potent and Durable Antithrombotic Effects.
Liang J, Nilsson S, Wikström J, et al. · JACC Basic Transl Sci 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.